GlassScriptPhysician profile
Mary R Kuns
NPI 1881614063
$1,916.30
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $393 · 2022: $462 · 2023: $732 · 2024: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.41 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $160.19 | 2021-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $158.33 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $145.00 | 2021-2023 | |
| Lilly USA, LLC | $126.19 | 2021-2024 | Jardiance, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $81.39 | 2023-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.95 | 2022-2023 | Jardiance |
| Exact Sciences Corporation | $59.59 | 2023-2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $52.41 | 2023 | Korlym |
| Dexcom, INC. | $49.79 | 2021-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $42.82 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $42.50 | 2023 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $42.43 | 2021 | |
| Esperion Therapeutics, INC. | $42.07 | 2021-2024 | Nexletol |
| Pfizer INC. | $33.15 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.77 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.83 | 2021-2023 | |
| Grifols USA, LLC | $28.71 | 2023 | Xembify |
| Glaxosmithkline, LLC. | $28.15 | 2022-2024 | Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $23.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.90 | 2024 | Gattex |
| Radius Health, INC. | $19.24 | 2023 | Tymlos |
| Amgen INC. | $19.20 | 2024 | Otezla, Repatha |
| Lundbeck LLC | $19.17 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $17.19 | 2024 | Auvelity |
| Ucb, INC. | $15.40 | 2024 | Briviact |
| Avanir Pharmaceuticals, INC. | $14.71 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.09 | 2023 | Xifaxan, Trulance |
| Braintree Laboratories, INC. | $13.90 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Kuns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.